Skip to main content
Clinical Trials/NCT01624181
NCT01624181
Completed
Not Applicable

Identification of Microbes Through Detection of Pathogen Specific Volatile Compound Patterns, Using Multi-capillary Column Coupled Ion Mobility Spectrometry (MCC-IMS) in the Setting of Hospital-acquired Pneumonia

University of Göttingen1 site in 1 country24 target enrollmentJune 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Lower Respiratory Tract Infection
Sponsor
University of Göttingen
Enrollment
24
Locations
1
Primary Endpoint
Time until pathogen identification through MCC-IMS
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

With this study the investigators want to determine, if a fast identification of germs, causing hospital-acquired infections of the lower respiratory tract, is possible through the use of MCC-IMS technology - a method that allows on time detection and identification of very small amounts of substances in gas samples. Therefore aspiration samples from the respiratory tracts of ventilated patients, which are suspected to develop such an infection, will be collected, cultivated and analyzed by MCC-IMS. The investigators want to determine if MCC-IMS diagnostic could be a faster alternative to conventional microbiological methods. The results of the MCC-IMS analyses therefore will be compared with results of conventional microbiological methods.

Detailed Description

In this clinical feasibility study it is to be investigated if MCC-IMS analyses over clinical samples from ventilated critically ill patients could be a fast and secure alternative to conventional microbiological diagnostic methods in the identification of human pathogenic microbes in the setting of hospital-acquired pneumonia. Therefore aspiration samples from intubated and ventilated critically ill patients, which are suspected to develop such an infection, will be collected and cultivated for a short period of time. The headspace over these cultures will be analyzed using MCC-IMS - a technology that allows on time detection and identification of very small amounts of substances in complex and humid gas samples. Conventional microbiological investigations, including MALDI-TOF, will be carried out parallel to the MCC-IMS analyses.

Registry
clinicaltrials.gov
Start Date
June 2012
End Date
September 2012
Last Updated
13 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University of Göttingen
Responsible Party
Principal Investigator
Principal Investigator

Dr. T. Perl

Principal Investigator

University of Göttingen

Eligibility Criteria

Inclusion Criteria

  • patient is at the hospital for more than 48 hours
  • patient is intubated and mechanically ventilated
  • clinical suspicion for an infection of the lower respiratory tract has been raised and decision for microbiological investigation of respiratory aspirate was made

Exclusion Criteria

  • patient is at the hospital for less than 48 hours
  • patient has been recruited for another clinical study
  • suspicion for an infection with a germ belonging to risk class 3 and 4 according to the german law (BioStoffV and TRBA, e.g. Mycobacterium tuberculosis)

Outcomes

Primary Outcomes

Time until pathogen identification through MCC-IMS

Time Frame: Up to 24 hours after sampling. Sampling (as an iclusion criterion) can be necessary anytime along the ICU stay of the patient (up to 12 months).

time from sampling until the availability of the results.

time until pathogen identification through conventional microbiological diagnostic methods

Time Frame: Up to 5 days after Sampling. Sampling (as an iclusion criterion) can be necessary anytime along the ICU stay of the patient (up to 12 months).

time from sampling until the availability of the results.

Secondary Outcomes

  • length of ICU stay(time from ICU admission to ICU discharge of study patients (up to 12 months))
  • Type and dosage of administered antibiotic therapy(approximately 5 days. Starting with the day the samples are taken. Ending with the day on which the results microbiological test are made avaiable.)
  • morbidity(Starts for study patients with the ICU admission and ends two days after the start of the initial antibiotic therapy. (up to 12 Months))

Study Sites (1)

Loading locations...

Similar Trials